مرکز تحقیقات علوم توانبخشی

VUITY

Presbyopia is the gradual age-related loss of accommodation, the ability of the crystalline lens of the eye to dynamically thicken and provide focus on nearby objects.

 Pilocarpine HCl ophthalmic solution 1.25% (VUITY, Allergan, an AbbVie company) is the first-in-class eye drop to treat presbyopia.

Mechanism:

The mechanism of action behind this drop works to constrict the pupil and contract the ciliary muscle, increasing the crystalline lens thickness and providing an increased depth of focus and field similar to that of a pinhole effect.

According to the table, other drops also have miotic properties like Nyxol or CSF-1, but they have not been approved yet.

Dose:

The recommended dosage for VUITY is one drop in each eye once daily. this solution begins to have an effect within 15 minutes and provides a sharper near image for 6 to 10 hours. One bottle, if used daily, should last about 1 month.

Side effects:

Headaches, eye redness and conjunctival hyperemia were seen in < 5% of patients. Post-market use has also revealed additional potential side effects such as a burning sensation on instillation, dimming of vision and an unanticipated amount of myopic shift. Other treatment emergent adverse events that were found included, blurred vision, eye pain, visual impairment, eye irritation as well as increased lacrimation.

Safety and precautions:

The use of VUITY ™is also not recommended in patients with iritis. Any patient with other eye diseases besides presbyopia should use extreme caution with VUITY™ as it can make these conditions worse.

Any patient wearing contact lenses should remove them prior to VUITY administration. If a patient is using multiple topical eye medications, they should be administered at least 5 minutes apart from each other.

by: Samin Oladi, Optometry student.